Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio

Tianjin CanSino Biologics, a clinical stage vaccine company raised $65 Million to advance its portfolio in North America, China and Africa; Shaanxi Kanghui Pharma completed a $52 million IPO in Shanghai; Qiming US Healthcare Fund led a $25 million Series B funding in Boston's ZappRx; China's Aier Eye Hospital will pay $166 million to acquire a majority stake in a chain of European ophthalmology clinics in Spain; Zhejiang POCTech Medical Corp, which makes a Glucose Monitoring device, closed a $14.5 million Series B funding; Qiang Sen International raised $14.5 million to expand its community clinic business; Suzhou Ribo Life Science will collaborate with San Diego's Ionis Pharma to develop RNA therapeutics; Chengdu's HitGen and Pfizer formed a collaboration to find drug leads; Antengene of Shanghai in-licensed East Asian rights to a Celgene cancer candidate; Beijing's BeiGene dosed the first patient in a China Phase II trial of its PD-1 candidate in Hodgkin lymphoma patients; and Sanming, a city in Fujian Province, offers a model for China healthcare reform: by taking on the system as a whole, it addressed several healthcare delivery problems that afflict most China cities.